tetano
Editor, Senior Moderator
J Infect Chemother. 2019 Dec 20. pii: S1341-321X(19)30370-8. doi: 10.1016/j.jiac.2019.12.002. [Epub ahead of print] [h=1]Duration of fever and PA/I38X-substituted virus emergence in patients treated with baloxavir in the 2018-2019 influenza season.[/h]
Ikematsu H[SUP]1[/SUP], Kawai N[SUP]2[/SUP], Tani N[SUP]3[/SUP], Chong Y[SUP]3[/SUP], Iwaki N[SUP]2[/SUP], Bando T[SUP]2[/SUP], Tanaka O[SUP]2[/SUP], Matsuura S[SUP]2[/SUP], Maeda T[SUP]2[/SUP], Doniwa K[SUP]2[/SUP].
[h=3]Author information[/h] 1 Japan Physicians Association, Influenza Study Group, Tokyo, Japan; Ricderca Clinica Co., Fukuoka, Japan. Electronic address: ikematsu@gray.plala.or.jp. 2 Japan Physicians Association, Influenza Study Group, Tokyo, Japan. 3 Medicine and Biosystemic Science, Kyushu University Graduate School of Medical Sciences, Fukuoka, Japan.
[h=3]Abstract[/h] Duration of fever and virus persistence after baloxavir administration were investigated in 81 outpatients, 16 with A(H1N1)pdm09 and 65 with A(H3N2) in the Japanese 2018-2019 influenza season. Only eight cases of A(H3N2) viruses were detected post-dose. PA/I38T-substituted viruses were detected in four (6.2%) of 65 A(H3N2) patients, at days 3 and 4, constituting 50% (4/8) of A(H3N2) detected post-dose. The median duration of fever was 26.0 h for A(H1N1)pdm09 and 20.3 h for A(H3N2). The median duration of fever for patients with PA/I38T-substituted viruses was 22.0 h, without significant difference to that of the patients in whom the mutated virus was not detected. Emergence of PA/I38T-substituted viruses after treatment with baloxavir was confirmed, but no significant prolongation of fever was observed in the four patients with PA/I38T-substituted virus emergence.
Copyright ? 2019 Japanese Society of Chemotherapy and The Japanese Association for Infectious Diseases. Published by Elsevier Ltd. All rights reserved.
[h=4]KEYWORDS:[/h] Baloxavir marboxil; Cap-dependent endonuclease inhibitor; Drug resistance; Duration of fever; Influenza; Mutation
PMID: 31870588 DOI: 10.1016/j.jiac.2019.12.002
Ikematsu H[SUP]1[/SUP], Kawai N[SUP]2[/SUP], Tani N[SUP]3[/SUP], Chong Y[SUP]3[/SUP], Iwaki N[SUP]2[/SUP], Bando T[SUP]2[/SUP], Tanaka O[SUP]2[/SUP], Matsuura S[SUP]2[/SUP], Maeda T[SUP]2[/SUP], Doniwa K[SUP]2[/SUP].
[h=3]Author information[/h] 1 Japan Physicians Association, Influenza Study Group, Tokyo, Japan; Ricderca Clinica Co., Fukuoka, Japan. Electronic address: ikematsu@gray.plala.or.jp. 2 Japan Physicians Association, Influenza Study Group, Tokyo, Japan. 3 Medicine and Biosystemic Science, Kyushu University Graduate School of Medical Sciences, Fukuoka, Japan.
[h=3]Abstract[/h] Duration of fever and virus persistence after baloxavir administration were investigated in 81 outpatients, 16 with A(H1N1)pdm09 and 65 with A(H3N2) in the Japanese 2018-2019 influenza season. Only eight cases of A(H3N2) viruses were detected post-dose. PA/I38T-substituted viruses were detected in four (6.2%) of 65 A(H3N2) patients, at days 3 and 4, constituting 50% (4/8) of A(H3N2) detected post-dose. The median duration of fever was 26.0 h for A(H1N1)pdm09 and 20.3 h for A(H3N2). The median duration of fever for patients with PA/I38T-substituted viruses was 22.0 h, without significant difference to that of the patients in whom the mutated virus was not detected. Emergence of PA/I38T-substituted viruses after treatment with baloxavir was confirmed, but no significant prolongation of fever was observed in the four patients with PA/I38T-substituted virus emergence.
Copyright ? 2019 Japanese Society of Chemotherapy and The Japanese Association for Infectious Diseases. Published by Elsevier Ltd. All rights reserved.
[h=4]KEYWORDS:[/h] Baloxavir marboxil; Cap-dependent endonuclease inhibitor; Drug resistance; Duration of fever; Influenza; Mutation
PMID: 31870588 DOI: 10.1016/j.jiac.2019.12.002